ARCTURUS THERAPEUTICS HOLDINGS INC. Earnings Per Share, Basic and Diluted
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Earnings Per Share, Basic and Diluted of -$1.94 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.94.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$1.47.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$2.05.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$2.07.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for fiscal 2021 was -$7.74.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for fiscal 2020 was -$3.55.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for fiscal 2019 was -$2.15.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic and diluted for fiscal 2018 was -$2.16.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$1.94 10-Q · filed 2022-05-09 | -$3.41 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$5.46 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$7.53 derived: net income ÷ weighted average shares · filed 2023-11-14 | |
| 2021-12-31 | -$1.47 10-K · filed 2022-03-01 | -$3.52 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$5.59 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$7.74 10-K · filed 2022-03-01 | |
| 2021-09-30 | -$2.05 10-K · filed 2022-03-01 | -$4.13 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$6.27 10-Q · filed 2021-11-09 | -$7.56 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2021-06-30 | -$2.07 10-K · filed 2022-03-01 | -$4.22 10-Q · filed 2021-08-10 | -$5.50 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$6.50 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2021-03-31 | -$2.15 10-Q · filed 2022-05-09 | -$3.42 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$4.39 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$5.11 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2020-12-31 | -$1.25 10-K · filed 2022-03-01 | -$2.18 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.81 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$3.55 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$0.92 10-K · filed 2022-03-01 | -$1.50 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.19 10-Q · filed 2021-11-09 | -$2.94 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-06-30 | -$0.55 10-K · filed 2022-03-01 | -$1.20 10-Q · filed 2021-08-10 | -$1.95 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.52 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-03-31 | -$0.67 10-K · filed 2022-03-01 | -$1.43 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.00 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$2.19 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2019-12-31 | -$0.76 10-K · filed 2021-03-01 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.50 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.15 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$0.56 10-K · filed 2021-03-01 | -$0.69 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.33 10-Q · filed 2020-11-09 | -$1.18 10-Q · filed 2019-11-08 | -$1.46 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2019-06-30 | -$0.07 10-K · filed 2021-03-01 | -$0.74 10-Q · filed 2020-08-10 | -$0.84 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.26 derived: net income ÷ weighted average shares · filed 2021-03-01 | |
| 2019-03-31 | -$0.68 10-K · filed 2021-03-01 | -$0.78 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.20 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.19 derived: net income ÷ weighted average shares · filed 2021-03-01 | |
| 2018-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$0.52 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.51 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.16 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$0.42 10-Q · filed 2019-11-08 | -$1.41 derived: net income ÷ weighted average shares · filed 2019-11-08 | -$2.07 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | -$0.99 10-Q · filed 2019-08-14 | -$1.65 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |